-
公开(公告)号：US20080153742A1
公开(公告)日：2008-06-26
申请号：US11869556
申请日：2007-10-09
Applicant: Mark I. Greene , Ramachandran Murali , Akihiro Hasegawa
Inventor： Mark I. Greene , Ramachandran Murali , Akihiro Hasegawa
CPC classification number: C07K14/70578 , A61K38/00
Abstract: Exocyclic peptide mimetics that disable Fas were developed. A three dimensional model of the Fas receptor-ligand complex was constructed and structurally predicted regions of the receptor that were relevant to binding ligand were used to create constrained peptide mimetics. Exocyclic anti-Fas peptide mimetics were identified that block Fas receptor-ligand interactions, and modulate Fas biological activity both in vitro and in vivo. The mimetics are useful, e.g., for treating Fas-related pathologies.
Abstract translation: 开发了禁用Fas的外来肽模拟物。 构建了Fas受体 - 配体复合物的三维模型，并且结构上预测与结合配体相关的受体区域用于产生约束肽模拟物。 鉴定了外环抗Fas肽模拟物阻断Fas受体 - 配体相互作用，并在体外和体内调节Fas生物活性。 模拟物可用于例如治疗Fas相关病理学。
-
62.发明授权Method, systems and kits for immuno-detection of epitopes expressed on molecules 有权用于在分子上表达的表位的免疫检测的方法，系统和试剂盒公开(公告)号：US07361464B2
公开(公告)日：2008-04-22
申请号：US10856057
申请日：2004-05-28
Applicant: Mark I. Greene , James Eberwine , Janet Estee Kacharmina , Hongtao Zhang
Inventor： Mark I. Greene , James Eberwine , Janet Estee Kacharmina , Hongtao Zhang
CPC classification number: G01N33/6878 , C07K16/06 , C07K16/32 , C07K2317/56 , C07K2317/565 , G01N33/532 , G01N33/6857
Abstract: Methods, systems and kits are provided for detecting molecules expressing a selected epitope in a sample through use of an epitope detector containing a single chain Fv for the selected epitope or a constrained epitope specific.CDR attached to an oligonucleotide.
Abstract translation: 提供了方法，系统和试剂盒，用于通过使用含有选定表位的单链Fv或与寡核苷酸连接的受限表位特异性CDR的表位检测器来检测在样品中表达选定表位的分子。
-
公开(公告)号：US06682739B1
公开(公告)日：2004-01-27
申请号：US09627775
申请日：2000-07-28
Applicant: Mark I. Greene , Ramachandran Murali , Kazuhiro Aoki , William Carle Horne , Roland Baron
Inventor： Mark I. Greene , Ramachandran Murali , Kazuhiro Aoki , William Carle Horne , Roland Baron
IPC: A61K3900
CPC classification number: C07K14/70578 , A61K38/00 , C07K14/7151 , Y10S514/885
Abstract: Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. The present invention also provides peptides and peptide analogues designed from a binding loop of a member of the tumor necrosis factor receptor (TNF-R) superfamily. According to the methods, an amount of an inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of an inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.
Abstract translation: 公开了抑制破骨细胞发生的方法和破骨细胞的活性。 公开了治疗具有骨丢失特征的患者的方法。 本发明还提供了由肿瘤坏死因子受体（TNF-R）超家族成员的结合环设计的肽和肽类似物。 根据该方法，向患者施用一定量的有效抑制破骨细胞发生的抑制剂。 公开了调节个体中树突状细胞成熟，T细胞增殖和/或CD40受体系统的方法。 所述方法包括向个体施用一定量的有效调节树突状细胞成熟，T细胞增殖和/或CD40受体系统的抑制剂的步骤。
-
公开(公告)号：US06673771B1
公开(公告)日：2004-01-06
申请号：US09628665
申请日：2000-07-28
Applicant: Mark I. Greene , Ramachandran Murali , Masahiko Kinosaki
Inventor： Mark I. Greene , Ramachandran Murali , Masahiko Kinosaki
IPC: A61K3800
CPC classification number: C07K14/70575 , A61K31/00 , A61K31/03 , A61K31/235 , A61K31/565 , A61K31/585 , A61K38/1709 , C07K5/1013 , C07K5/1016 , C07K5/1021
Abstract: Methods of inhibiting osteoclastogenesis and the activity of osteoclasts are disclosed. Methods of treating patients who have diseases characterized bone loss are disclosed. According to the methods, an amount of a TRANCE/RANK inhibitor effective to inhibit osteoclastogenesis is administered to the patient. Pharmaceutical compositions which comprise TRANCE/RANK inhibitor in an amount effective to inhibit osteoclastogenesis. Methods of modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems in an individual are disclosed. The methods comprise the step of administering to the individual an amount of a TRANCE/RANK inhibitor effective to modulating dendritic cell maturation, T cell proliferation, and/or CD40 receptor systems.
Abstract translation: 公开了抑制破骨细胞发生的方法和破骨细胞的活性。 公开了治疗具有骨丢失特征的患者的方法。 根据该方法，向患者施用一定量的有效抑制破骨细胞发生的TRANCE / RANK抑制剂。 含有有效抑制破骨细胞发生量的TRANCE / RANK抑制剂的药物组合物。 公开了调节个体中树突状细胞成熟，T细胞增殖和/或CD40受体系统的方法。 所述方法包括向个体施用一定量的有效调节树突状细胞成熟，T细胞增殖和/或CD40受体系统的TRANCE / RANK抑制剂的步骤。
-
65.发明授权Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses 失效由肿瘤坏死因子受体超家族的结合位点设计的肽和肽类似物及其用途公开(公告)号：US06265535B1
公开(公告)日：2001-07-24
申请号：US08866545
申请日：1997-05-30
Applicant: Mark I. Greene , Ramachandran Murali , Wataru Takasaki
Inventor： Mark I. Greene , Ramachandran Murali , Wataru Takasaki
IPC: A61K3812
CPC classification number: C07K14/70578 , A61K38/00 , Y02A50/411
Abstract: The present invention relates to peptides and peptide analogues designed from a binding loop of a member of the tumor necrosis factor receptor (TNF-R) superfamily. In particular, it relates to cyclic peptides and peptide analogues designed from a binding loop of TNF-R which inhibit TNF binding to its cellular receptors, and methods of making and using such compounds to inhibit the biological activities of TNF.
Abstract translation: 本发明涉及由肿瘤坏死因子受体（TNF-R）超家族成员的结合环设计的肽和肽类似物。 特别地，本发明涉及由抑制TNF与其细胞受体结合的TNF-R的结合环设计的环肽和肽类似物，以及制备和使用这些化合物抑制TNF的生物学活性的方法。
-
Patent Agency Ranking
公开(公告)号：US5837523A
公开(公告)日：1998-11-17
申请号：US737269
申请日：1997-02-11
Applicant: Mark I. Greene , Xiaolan Qian
Inventor： Mark I. Greene , Xiaolan Qian
Abstract: Nucleic acid molecules that comprise a nucleotide sequence that encodes a protein that dimerizes with epidermal growth factor receptor and p185 and lacks tyrosine kinase activity are disclosed. The nucleic acid molecules in combination with delivery components are disclosed.
Abstract translation: PCT No.PCT / US95 / 05614 Sec。 371日期1997年2月11日 102（e）日期1997年2月11日PCT提交1995年5月5日PCT公布。 WO95 / 30331 PCT出版物 日期：1995年11月16日公开了包含编码与表皮生长因子受体和p185二聚化并缺乏酪氨酸激酶活性的蛋白质的核苷酸序列的核酸分子。 公开了与递送组分组合的核酸分子。
-
公开(公告)号：US5705157A
公开(公告)日：1998-01-06
申请号：US347018
申请日：1994-11-30
Applicant: Mark I. Greene
Inventor： Mark I. Greene
IPC: A61K38/00 , C07K16/28 , C07K16/32 , A61K39/395 , C07K16/30
CPC classification number: C07K16/32 , C07K16/2863 , A61K38/00 , C07K2317/73
Abstract: The present invention provides methods and therapeutic compositions for treatment of mammalian tumors wherein the cells of such tumor express both epidermal growth factor receptor and p185neu, p185c-neu or a homologue of p185neu or p185c-neu and the epidermal growth factor. At least one antibody specific for epidermal growth factor receptor, monoclonal antibody 425, and at least one antibody specific for p185neu, p185c-neu or a homologue of p185neu or p185c-neu, monoclonal antibody 7.16.4, are administered to the mammal in an amount effective to reduce tumor growth.
Abstract translation: 本发明提供用于治疗哺乳动物肿瘤的方法和治疗组合物，其中这种肿瘤的细胞表达表皮生长因子受体和p185neu，p185c-neu或p185neu或p185c-neu的同源物和表皮生长因子。 对于表皮生长因子受体，单克隆抗体425和至少一种对p185neu，p185c-neu或p185neu或p185c-neu，单克隆抗体7.16.4的同源物具有特异性的抗体，至少一种抗体以 量有效减少肿瘤生长。
-
公开(公告)号：US5663144A
公开(公告)日：1997-09-02
申请号：US433318
申请日：1995-05-03
Applicant: Mark I. Greene , Xin Zhang
Inventor： Mark I. Greene , Xin Zhang
Abstract: Novels peptides and pharmaceutical compositions comprising the same are disclosed. Conjugated compositions peptides linked to detectable agents and/or cytotoxic agents. are disclosed. Method of detecting tumors that have p185 on tumor cell surfaces are disclosed. Methods of preventing transformation of a normal cell into a tumor cell in an individual at risk of developing a tumor having tumor cells which have p185 on their surfaces are disclosed. Methods of treating an individual who has cancer characterized by tumor cells that have a p185 on their cell surfaces are disclosed.
Abstract translation: 公开了新颖的肽和包含其的药物组合物。 与可检测的试剂和/或细胞毒性剂连接的共轭组合物肽。 被披露。 公开了检测肿瘤细胞表面上具有p185的肿瘤的方法。 公开了防止正常细胞转化成具有在其表面具有p185的肿瘤细胞的肿瘤的风险中的个体的肿瘤细胞的方法。 公开了在细胞表面处理具有p185的肿瘤细胞特征的癌症的个体的方法。
-
公开(公告)号：USRE32833E
公开(公告)日：1989-01-17
申请号：US4172
申请日：1986-12-23
Applicant: Mark I. Greene , Bernard N. Fields
Inventor： Mark I. Greene , Bernard N. Fields
CPC classification number: C07K16/4216 , C07K16/10 , G01N33/686 , A61K38/00
Abstract: Mammals are vaccinated against infectious organisms and polypeptides are screened for utility as vaccines by a complementing set of monoclonal antibodies, the first of which antibodies binds specifically to the site on the organism which itself binds specifically to a receptor on a host cell of the mammal, and the second of which binds specifically to the first. Vaccination is done with the second antibody alone, and screening is done by determining whether the polypeptide binds to the first antibody.
-
公开(公告)号：US09751830B2
公开(公告)日：2017-09-05
申请号：US13634368
申请日：2011-03-07
Applicant: Ramachandran Murali , Mark I. Greene
Inventor： Ramachandran Murali , Mark I. Greene
IPC: C07C233/25 , A61K31/075 , C07C217/18 , C07C217/20 , C07C233/18 , C07C217/32
CPC classification number: C07C233/25 , A61K31/075 , C07C217/18 , C07C217/20 , C07C217/32 , C07C233/18
Abstract: The present invention relates to compounds of formula (I) that are inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-α mediated conditions: Formula (I)
-
-
-
-
-
-
-
-
-
Search Results
90
records
(took 0.027 seconds)
